Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles platform, to develop novel multifunctional biologics against one target in oncology and another in immunology.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $64.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2024
Details:
The financing will be used to continue advancing our promising Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Amplitude Ventures
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 06, 2023
Details:
Under the collaboration, Gilead leverages Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein and antiboby-based therapeutics for oncology and inflammatory diseases.
Lead Product(s): Antibody-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $306.0 million Upfront Cash: $66.0 million
Deal Type: Collaboration August 15, 2023
Details:
The lead program is a multifunctional therapeutic with one subunit that targets the IL2R gamma receptor, a subunit that targets the IL2R beta receptor and other subunits that bind to cell surface proteins on a specific subset of T cells.
Lead Product(s): Antibody-based Multifunctional Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 14, 2021